Description: Otonomy, Inc. develops and commercializes therapeutics for the treatment of ear diseases and disorders primarily in the United States. Its lead product candidate is AuriPro, a sustained-exposure antibiotic, which is in Phase III clinical trials to treat pediatric patients with middle ear effusion at the time of tympanostomy tube placement surgery. The company also develops OTO-104, a sustained-exposure formulation of the steroid dexamethasone that is in a Phase IIb clinical trial for the treatment of patients with Ménière's disease; and OTO-311, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in preclinical development as a potential treatment for tinnitus. Otonomy, Inc. was founded in 2008 and is headquartered in San Diego, California.
Home Page: www.otonomy.com
OTIC Technical Analysis
4796 Executive Drive
San Diego,
CA
92121
United States
Phone:
619 323 2200
Officers
| Name | Title |
|---|---|
| Dr. David Allen Weber | Pres, CEO & Director |
| Mr. Paul E. Cayer | Chief Financial & Bus. Officer |
| Dr. Allen F. Ryan Ph.D. | Co-Founder and Member of the Advisory Panel |
| Dr. Rick Adam Friedman M.D., Ph.D. | Co-Founder and Member of the Advisory Panel |
| Dr. Alan Charles Foster Ph.D. | Chief Scientific Officer |
| Ms. Breianna Bowen | VP of HR |
| Ms. Barbara M. Finn | Sr. VP of Regulatory Affairs & Quality Assurance |
| Dr. Fabrice Piu Ph.D. | Sr. VP of Preclinical Devel. |
| Mr. David Skarinsky | Sr. VP of Clinical |
| Mr. James Branch CPA | VP of Fin. & Controller |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.328 |
| Price-to-Sales TTM: | 3187.6096 |
| IPO Date: | 2014-08-13 |
| Fiscal Year End: | December |
| Full Time Employees: | 51 |